CN109908312A - 一种痔疮膏及其制备方法 - Google Patents
一种痔疮膏及其制备方法 Download PDFInfo
- Publication number
- CN109908312A CN109908312A CN201910365687.1A CN201910365687A CN109908312A CN 109908312 A CN109908312 A CN 109908312A CN 201910365687 A CN201910365687 A CN 201910365687A CN 109908312 A CN109908312 A CN 109908312A
- Authority
- CN
- China
- Prior art keywords
- parts
- acne cream
- calcined
- radix angelicae
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000006071 cream Substances 0.000 title claims abstract description 69
- 208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 68
- 206010000496 acne Diseases 0.000 title claims abstract description 68
- 238000002360 preparation method Methods 0.000 title claims abstract description 30
- 241001313857 Bletilla striata Species 0.000 claims abstract description 35
- 240000009138 Curcuma zedoaria Species 0.000 claims abstract description 35
- 240000003152 Rhus chinensis Species 0.000 claims abstract description 31
- 235000014220 Rhus chinensis Nutrition 0.000 claims abstract description 31
- 229910052602 gypsum Inorganic materials 0.000 claims abstract description 31
- 239000010440 gypsum Substances 0.000 claims abstract description 31
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 29
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 29
- 229940116229 borneol Drugs 0.000 claims abstract description 29
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 29
- 229940105847 calamine Drugs 0.000 claims abstract description 29
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 29
- 229910052864 hemimorphite Inorganic materials 0.000 claims abstract description 29
- 239000002994 raw material Substances 0.000 claims abstract description 29
- 235000014692 zinc oxide Nutrition 0.000 claims abstract description 29
- 239000011787 zinc oxide Substances 0.000 claims abstract description 29
- CPYIZQLXMGRKSW-UHFFFAOYSA-N zinc;iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+3].[Fe+3].[Zn+2] CPYIZQLXMGRKSW-UHFFFAOYSA-N 0.000 claims abstract description 29
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 28
- 241000717739 Boswellia sacra Species 0.000 claims abstract description 27
- 239000004863 Frankincense Substances 0.000 claims abstract description 27
- 244000157790 Buglossoides arvense Species 0.000 claims abstract description 26
- 235000004256 Buglossoides arvense Nutrition 0.000 claims abstract description 26
- 230000002829 reductive effect Effects 0.000 claims abstract description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 33
- 244000061456 Solanum tuberosum Species 0.000 claims description 26
- 235000002595 Solanum tuberosum Nutrition 0.000 claims description 26
- 241000270288 Gekko Species 0.000 claims description 22
- 238000002156 mixing Methods 0.000 claims description 21
- 239000000341 volatile oil Substances 0.000 claims description 20
- 238000003756 stirring Methods 0.000 claims description 16
- WTQYWNWRJNXDEG-UHFFFAOYSA-N 6-Hydroxy-hyoscyamin Natural products CN1C(C2)CC(O)C1CC2OC(=O)C(CO)C1=CC=CC=C1 WTQYWNWRJNXDEG-UHFFFAOYSA-N 0.000 claims description 15
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 15
- QQILFGKZUJYXGS-UHFFFAOYSA-N Indigo dye Chemical compound C1=CC=C2C(=O)C(C3=C(C4=CC=CC=C4N3)O)=NC2=C1 QQILFGKZUJYXGS-UHFFFAOYSA-N 0.000 claims description 15
- WTQYWNWRJNXDEG-LEOABGAYSA-N anisodamine Chemical compound C1([C@@H](CO)C(=O)O[C@@H]2C[C@H]3[C@@H](O)C[C@@H](C2)N3C)=CC=CC=C1 WTQYWNWRJNXDEG-LEOABGAYSA-N 0.000 claims description 15
- 241000931143 Gleditsia sinensis Species 0.000 claims description 12
- 241000219784 Sophora Species 0.000 claims description 12
- 235000018597 common camellia Nutrition 0.000 claims description 12
- 240000004980 Rheum officinale Species 0.000 claims description 11
- 235000008081 Rheum officinale Nutrition 0.000 claims description 11
- 238000004821 distillation Methods 0.000 claims description 9
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 8
- 229940099259 vaseline Drugs 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 240000001548 Camellia japonica Species 0.000 claims description 5
- 239000005711 Benzoic acid Substances 0.000 claims description 4
- 235000010233 benzoic acid Nutrition 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 3
- 229960005150 glycerol Drugs 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 39
- 208000014617 hemorrhoid Diseases 0.000 abstract description 36
- 239000003814 drug Substances 0.000 abstract description 35
- 235000014375 Curcuma Nutrition 0.000 abstract description 30
- 235000003405 Curcuma zedoaria Nutrition 0.000 abstract description 30
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 abstract description 30
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 abstract description 30
- 235000019509 white turmeric Nutrition 0.000 abstract description 30
- 229940079593 drug Drugs 0.000 abstract description 22
- 208000002193 Pain Diseases 0.000 abstract description 15
- 241000721047 Danaus plexippus Species 0.000 abstract description 13
- 230000000857 drug effect Effects 0.000 abstract description 5
- 230000001225 therapeutic effect Effects 0.000 abstract description 5
- 230000003902 lesion Effects 0.000 abstract description 4
- 230000001114 myogenic effect Effects 0.000 abstract description 4
- 230000000144 pharmacologic effect Effects 0.000 abstract description 4
- 239000002674 ointment Substances 0.000 abstract description 3
- 206010003694 Atrophy Diseases 0.000 abstract description 2
- 230000037444 atrophy Effects 0.000 abstract description 2
- 239000000955 prescription drug Substances 0.000 abstract description 2
- 230000008961 swelling Effects 0.000 abstract description 2
- 244000164480 Curcuma aromatica Species 0.000 abstract 1
- 244000163122 Curcuma domestica Species 0.000 description 30
- 238000000034 method Methods 0.000 description 23
- 210000004369 blood Anatomy 0.000 description 22
- 239000008280 blood Substances 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 239000000843 powder Substances 0.000 description 17
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 13
- 230000006870 function Effects 0.000 description 12
- 208000035861 hematochezia Diseases 0.000 description 12
- 210000004072 lung Anatomy 0.000 description 12
- 239000002002 slurry Substances 0.000 description 12
- 230000008569 process Effects 0.000 description 11
- 230000023597 hemostasis Effects 0.000 description 9
- 230000000740 bleeding effect Effects 0.000 description 8
- 239000012141 concentrate Substances 0.000 description 8
- 235000019441 ethanol Nutrition 0.000 description 8
- 231100000614 poison Toxicity 0.000 description 8
- 241000209507 Camellia Species 0.000 description 7
- 206010007247 Carbuncle Diseases 0.000 description 7
- 206010011224 Cough Diseases 0.000 description 7
- 208000000616 Hemoptysis Diseases 0.000 description 7
- 208000032843 Hemorrhage Diseases 0.000 description 7
- 208000025865 Ulcer Diseases 0.000 description 7
- 230000000202 analgesic effect Effects 0.000 description 7
- 230000000844 anti-bacterial effect Effects 0.000 description 7
- 230000003110 anti-inflammatory effect Effects 0.000 description 7
- 208000034158 bleeding Diseases 0.000 description 7
- 231100000319 bleeding Toxicity 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 231100000397 ulcer Toxicity 0.000 description 7
- 206010010774 Constipation Diseases 0.000 description 6
- 238000007654 immersion Methods 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 102000016938 Catalase Human genes 0.000 description 5
- 108010053835 Catalase Proteins 0.000 description 5
- 208000034507 Haematemesis Diseases 0.000 description 5
- 206010000269 abscess Diseases 0.000 description 5
- 208000001848 dysentery Diseases 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 239000002574 poison Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 201000004624 Dermatitis Diseases 0.000 description 4
- 241001062009 Indigofera Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 210000000436 anus Anatomy 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- AMWRITDGCCNYAT-UHFFFAOYSA-L hydroxy(oxo)manganese;manganese Chemical compound [Mn].O[Mn]=O.O[Mn]=O AMWRITDGCCNYAT-UHFFFAOYSA-L 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 241001523383 Achnatherum Species 0.000 description 3
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 3
- 206010053615 Thermal burn Diseases 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 230000000767 anti-ulcer Effects 0.000 description 3
- 208000002399 aphthous stomatitis Diseases 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 3
- 239000001685 glycyrrhizic acid Substances 0.000 description 3
- 229960004949 glycyrrhizic acid Drugs 0.000 description 3
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 3
- 235000019410 glycyrrhizin Nutrition 0.000 description 3
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 3
- 208000006750 hematuria Diseases 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000035900 sweating Effects 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 230000002087 whitening effect Effects 0.000 description 3
- 229910000010 zinc carbonate Inorganic materials 0.000 description 3
- OPFTUNCRGUEPRZ-QLFBSQMISA-N (-)-beta-elemene Chemical compound CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@H](C(C)=C)C1 OPFTUNCRGUEPRZ-QLFBSQMISA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 206010063409 Acarodermatitis Diseases 0.000 description 2
- 244000061520 Angelica archangelica Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- NJICGAVMYWKCMW-GWJXCKMPSA-N Dipterocarpol Chemical compound C1CC(=O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@@](C)(O)CCC=C(C)C)[C@H]4CC[C@@H]3[C@]21C NJICGAVMYWKCMW-GWJXCKMPSA-N 0.000 description 2
- 201000000297 Erysipelas Diseases 0.000 description 2
- 206010018612 Gonorrhoea Diseases 0.000 description 2
- 235000001287 Guettarda speciosa Nutrition 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 206010025421 Macule Diseases 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 241000233855 Orchidaceae Species 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 241001529246 Platymiscium Species 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000447727 Scabies Species 0.000 description 2
- 206010041497 Spermatorrhoea Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 244000299492 Thespesia populnea Species 0.000 description 2
- 235000009430 Thespesia populnea Nutrition 0.000 description 2
- 241000130764 Tinea Species 0.000 description 2
- 208000002474 Tinea Diseases 0.000 description 2
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 244000178320 Vaccaria pyramidata Species 0.000 description 2
- 235000010587 Vaccaria pyramidata Nutrition 0.000 description 2
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical group [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 229940097275 indigo Drugs 0.000 description 2
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 235000008935 nutritious Nutrition 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 201000010727 rectal prolapse Diseases 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 208000005687 scabies Diseases 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 210000000697 sensory organ Anatomy 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- 239000011667 zinc carbonate Substances 0.000 description 2
- OPFTUNCRGUEPRZ-UHFFFAOYSA-N (+)-beta-Elemen Natural products CC(=C)C1CCC(C)(C=C)C(C(C)=C)C1 OPFTUNCRGUEPRZ-UHFFFAOYSA-N 0.000 description 1
- CJGSNPCDEYCMDA-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-4-fluoro-6-methylphenol Chemical compound CN(C)CC1=CC(F)=CC(C)=C1O CJGSNPCDEYCMDA-UHFFFAOYSA-N 0.000 description 1
- NJICGAVMYWKCMW-UHFFFAOYSA-N 20 R-Hydroxydammarenon Natural products C1CC(=O)C(C)(C)C2CCC3(C)C4(C)CCC(C(C)(O)CCC=C(C)C)C4CCC3C21C NJICGAVMYWKCMW-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 241000207965 Acanthaceae Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- PFCVZKFJHRCLCC-MTYXOXLRSA-N Alphitolic acid Natural products CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@@H](CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O PFCVZKFJHRCLCC-MTYXOXLRSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 241000208223 Anacardiaceae Species 0.000 description 1
- 206010002153 Anal fissure Diseases 0.000 description 1
- 208000016583 Anus disease Diseases 0.000 description 1
- 241001124076 Aphididae Species 0.000 description 1
- 235000004359 Artemisia pontica Nutrition 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 241001313855 Bletilla Species 0.000 description 1
- 241001608538 Boswellia Species 0.000 description 1
- 229910021532 Calcite Inorganic materials 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 241000905957 Channa melasoma Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 244000301850 Cupressus sempervirens Species 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- UFJPCTSKTPSJTK-UHFFFAOYSA-N Dryobalanone Natural products C1CC(=O)C(C)(C)C2CCC3(C)C4(C)CCC(C(O)(CO)CCC=C(C)C)C4CCC3C21C UFJPCTSKTPSJTK-UHFFFAOYSA-N 0.000 description 1
- 240000005636 Dryobalanops aromatica Species 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 208000009531 Fissure in Ano Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 241000270291 Gekkonidae Species 0.000 description 1
- 206010058109 Hangnail Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021137 Hypovolaemia Diseases 0.000 description 1
- 241000755540 Indocalamus Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 231100000111 LD50 Toxicity 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- 241001071917 Lithospermum Species 0.000 description 1
- 206010048961 Localised oedema Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 240000000233 Melia azedarach Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- PSZDOEIIIJFCFE-UHFFFAOYSA-N Oleanolic alcohol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(CO)CCC(C)(C)CC5C4=CCC3C21C PSZDOEIIIJFCFE-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 241000972672 Phellodendron Species 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 241000219050 Polygonaceae Species 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241000282806 Rhinoceros Species 0.000 description 1
- 241001516602 Schlechtendalia chinensis Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 206010042170 Strangury Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 206010044684 Trismus Diseases 0.000 description 1
- 206010061577 Ulcer haemorrhage Diseases 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010051373 Wound haemorrhage Diseases 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- PGTXKIZLOWULDJ-UHFFFAOYSA-N [Mg].[Zn] Chemical compound [Mg].[Zn] PGTXKIZLOWULDJ-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 201000004484 acute conjunctivitis Diseases 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 210000002255 anal canal Anatomy 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000146 antalgic effect Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- JXSVIVRDWWRQRT-UYDOISQJSA-N asiatic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C JXSVIVRDWWRQRT-UYDOISQJSA-N 0.000 description 1
- 229940011658 asiatic acid Drugs 0.000 description 1
- LBGFKBYMNRAMFC-PYSQTNCISA-N asiatic acid Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@]2(C)[C@H]1C)C(=O)O LBGFKBYMNRAMFC-PYSQTNCISA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 229910001748 carbonate mineral Inorganic materials 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000004320 controlled atmosphere Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- PSZDOEIIIJFCFE-OSQDELBUSA-N erythrodiol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(CO)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C PSZDOEIIIJFCFE-OSQDELBUSA-N 0.000 description 1
- HTZRWCSRPTWJCT-UHFFFAOYSA-N erythrodiol Natural products CC1(C)CCC2(CO)CCC3C(CCC4C3(C)CCC5C(C)(C)C(O)CCC45C)C2C1 HTZRWCSRPTWJCT-UHFFFAOYSA-N 0.000 description 1
- CLXOLTFMHAXJST-UHFFFAOYSA-N esculentic acid Natural products C12CC=C3C4CC(C)(C(O)=O)CCC4(C(O)=O)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(CO)C CLXOLTFMHAXJST-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 208000010553 multiple abscesses Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000002940 repellent Effects 0.000 description 1
- 239000005871 repellent Substances 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000036228 toxication Effects 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 208000025301 tympanitis Diseases 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 235000004416 zinc carbonate Nutrition 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供一种痔疮膏及其制备方法,涉及药膏技术领域。一种痔疮膏,包括按重量份数计的以下原料:黄柏6‑15份;煅石膏25‑35份;紫草5‑15份;当归15‑25份;莪术5‑15份;乳香15‑25份;五倍子5‑15份;煅龙骨25‑35份;白芨5‑15份;冰片1‑5份;珍珠25‑35份;炉甘石25‑35份。煅石膏、当归、乳香、煅龙骨、珍珠以及炉甘石用作君药,主要达到使痔疮快速萎缩,并能明显减轻患者痛苦的作用。其余各药共同作为臣药,主要起加强君药药效的作用,防止君药药性的流失,保障患者病灶部位能够充分吸收君药中的有效成分,从而保证了痔疮的治疗效果。以上诸药共同取到清热解毒、消肿止痛、收敛生肌的功效。
Description
技术领域
本发明涉及药膏技术领域,具体而言,涉及一种痔疮膏及其制备方法。
背景技术
痔疮是肛门直肠下端和肛管皮肤下的静脉丛发生扩张和屈曲所形成的一个或多个柔软的静脉团的一种慢性疾病,这种静脉团俗称痔核,按其生成部位不同分为内痔、外痔和混合痔三种。中药认为痔疮多因湿热内积;久坐;久立;饮食辛辣或临产用力;大便秘结等导致浊气瘀血流注肛门而患病。痔疮的并发症:1.引起脱垂;嵌顿甚至坏死,2.长期便血易致贫血,3.容易引发妇科炎症,4.导致肛周长期湿疹。患痔日久者,因年老体弱,肛门松弛,气虚不能提升,痔核尤其容易脱出,且不易自行回复,严重影响了患者的工作和生活。痔疮可通过局部用药对其进行治疗,现有的痔疮膏治疗效果还有待提高。
发明内容
本发明的目的在于提供一种痔疮膏,其具有较好的治疗效果。
本发明的另一目的在于提供一种痔疮膏的制备方法,该方法简单高效,适合批量生产。
本发明解决其技术问题是采用以下技术方案来实现的。
本发明提出一种痔疮膏,其主要包括按重量份数计的以下原料:
黄柏6-15份;煅石膏25-35份;紫草5-15份;当归15-25份;莪术5-15份;乳香15-25份;五倍子5-15份;煅龙骨25-35份;白芨5-15份;冰片1-5份;珍珠25-35份;炉甘石25-35份。
本发明提出一种痔疮膏制备方法,包括:将黄柏、煅石膏、紫草、当归、莪术、乳香、五倍子、煅龙骨、白芨、冰片、珍珠和炉甘石与凡士林、甘油混合制得痔疮膏。
本发明实施例提供的痔疮膏及其制备方法至少具有以下有益效果:
本发明实施例提供一种痔疮膏,包括按重量份数计的以下原料:黄柏6-15份;煅石膏25-35份;紫草5-15份;当归15-25份;莪术5-15份;乳香15-25份;五倍子5-15份;煅龙骨25-35份;白芨5-15份;冰片1-5份;珍珠25-35份;炉甘石25-35份。一种上述痔疮膏的制备方法:将黄柏、煅石膏、紫草、当归、莪术、乳香、五倍子、煅龙骨、白芨、冰片、珍珠和炉甘石与凡士林、甘油混合制得痔疮膏。煅石膏、当归、乳香、煅龙骨、珍珠以及炉甘石用作君药,主要达到使痔疮快速萎缩,并能明显减轻患者痛苦的作用,还具有清热解毒、抗菌消炎、破瘀止血以及收敛止痛的功效。黄柏、紫草、莪术、五倍子、白芨和冰片共同作为臣药,主要起加强君药药效的作用,防止君药药性的流失,保障患者病灶部位能够充分吸收君药中的有效成分,从而保证了痔疮的治疗效果。
具体实施方式
为使本发明实施例的目的;技术方案和优点更加清楚,下面将对本发明实施例中的技术方案进行清楚;完整地描述。实施例中未注明具体条件者,按照常规条件或制造商建议的条件进行。所用试剂或仪器未注明生产厂商者,均为可以通过市售购买获得的常规产品。
下面对本发明实施例的痔疮膏和制备方法进行具体说明。
本发明实施例提供一种痔疮膏,其主要包括按重量份数计的以下原料:
黄柏6-15份;煅石膏25-35份;紫草5-15份;当归15-25份;莪术5-15份;乳香15-25份;五倍子5-15份;煅龙骨25-35份;白芨5-15份;冰片1-5份;珍珠25-35份;炉甘石25-35份。
煅石膏为白色的粉末或酥松块状物,表面透出微红色的光泽,不透明。体较轻,质软,易碎,捏之成粉。煅石膏为石膏的炮制品,可以取净石膏,在无烟炉火中或坩锅内煅至酥松,取出晾凉,打碎即得。煅石膏功能主治:收湿、生肌、敛疮、止血,外治溃疡不敛、湿疹瘙痒、水火烫伤、外伤出血。
当归,别名干归、秦哪、西当归、岷当归、金当归、当归身、涵归尾、当归曲、土当归,多年生草本。其根可入药,是最常用的中药之一,具有补血和血,调经止痛,润燥滑肠、抗癌、抗老防老、免疫之功效。
乳香为橄榄科植物乳香树及同属植物树皮渗出的树脂。性辛、苦、温。入心、肝、脾经。具有活血、行气、止痛、抑菌等功用。可用于治疗瘀阻气滞的脘腹疼痛,风湿痹痛,跌打损伤,痛经,产后腹痛等。
龙骨为古代哺乳动物如象类、犀牛类、三趾马等的骨胳的化石。取刷净的龙骨,在无烟的炉火上或坩埚内煅红透,取出,放凉,碾碎即为煅龙骨。煅龙骨具有镇惊安神,敛汗固精,止血涩肠,生肌敛疮的作用。用治惊痫癫狂,怔忡健忘,失眠多梦,自汗盗汗,遗精淋浊,吐衄便血,崩漏带下,泻痢脱肛,溃疡久不收口。
珍珠具有安神定惊、清热滋阴、明目去翳、解毒生肌等功效,现代研究还表明珍珠在提高人体免疫力、延缓衰老、祛斑美白、补充钙质等方面都具有独特的作用。在《本草纲目》中特别记载了:“珍珠味咸甘寒无毒,镇心点目;珍珠涂面,令人润泽好颜色。涂手足,去皮肤逆胪;坠痰,除面斑,止泻;除小儿惊热,安魂魄;止遗精白浊,解痘疗毒。……令光泽洁白”等。同时,它还记载了珍珠药用的多种方法。
炉甘石为碳酸盐类矿物方解石族菱锌矿。主要成分为碳酸锌(ZnC03),尚含少量氧化钙(CaO),氧化镁(MgO),氧化铁(Fe203),氧化锰(MnO)。炉甘石为不溶于水的天然碳酸锌,广用于皮肤科,作为中度的防腐、收敛、保护、治疗皮肤炎症或表面创伤。外用可抑制局部葡萄球菌生长,能部分吸收创面分泌液,有收敛、保护作用。
煅石膏、当归、乳香、煅龙骨、珍珠以及炉甘石用作君药,主要达到使痔疮快速萎缩,并能明显减轻患者痛苦的作用,还具有清热解毒、抗菌消炎、破瘀止血以及收敛止痛的功效。
紫草是紫草科紫草属多年生草本植物,性寒,味苦。功能主治:凉血,活血,清热,解毒。治温热斑疹,湿热黄疸,紫癜,吐、衄、尿血,淋浊,热结便秘,烧伤,湿疹,丹毒,痈疡。
黄柏也称黄檗、元柏、檗木,是芸香科黄檗属落叶乔木。黄柏的树皮内层经炮制后入药。味苦,性寒。清热解毒,泻火燥湿。主治急性细菌性痢疾、急性肠炎、急性黄疸型肝炎、泌尿系统感染等炎症。外用治火烫伤、中耳炎、急性结膜炎等。
莪术,别称莪药、莪茂、青姜、黑心姜、姜黄,为多年生宿根草本。其根茎供药用,主治“气血凝滞,心腹胀痛,症瘕,积聚,宿食不消,妇女血瘀经闭,跌打损伤作痛,还有行气解郁,破瘀,止痛、抗菌、抗炎的功用。
五倍子为漆树科植物盐肤木、青麸杨和红麸杨等树上寄生倍蚜科昆虫角倍蚜或倍蛋蚜后形成的虫瘿。当然,本发明实施例中所用五倍子是能直接使用的药材(即已除去虫卵)。五倍子味酸,涩,性寒,归肺、大肠、肾经。其具有敛肺、止汗、涩肠、固精、止血、解毒等功效。主治:肺虚久咳、自汗盗汗、久痢久泻、脱肛、遗精、白浊、各种出血、痈肿疮疖。
白芨又名连及草、甘根、白及、箬兰、朱兰、紫兰、紫蕙、百笠等。白芨补肺,止血,消肿,生肌,敛疮。治肺伤咳血,衄血,金疮出血,痈疽肿毒,溃疡疼痛,汤火灼伤,手足皲裂。现代药理学也表明,白芨具有以下作用:
1、收敛止血。白芨的止血作用,是因为它能增强血小板因子活性,在较短时间内凝血,使得凝血酶快速生成,同时抑制纤维蛋白溶酶活性,可以起到局部止血的作用。白芨的收敛止血功效,可以用于咳血、吐血、外伤出血、肺结核咳血、溃疡出血等症状。白芨的止血与三七的止血不一样。白芨是收敛止血,而三七是散瘀止血。
2、消肿生肌。白芨具有消肿生肌的功效,能治疗生疮出血、溃疡、痈疽肿毒、手足皲裂、肛裂、疮疡等。
3、补肺。白芨味苦、甘而涩,性微寒,入肺经,具有补肺的功效,对治疗肺痿肺烂、肺结核有一定的效果。
4、美容。白芨含有丰富的挥发油及粘液质等成分,具有美白祛斑的功效,磨成粉外用涂擦,可以消除脸上痤疮留下的痕迹,滋润、美白肌肤,起到美容的效果。
5、抗菌。白芨对于大型结核杆菌有显著抑制作用,也能对革兰氏阳性菌起到抑制作用。
6、抗溃疡。白芨具有抗溃疡的作用,白芨具有高度的粘性,可在胃内形成胶状膜,能促使溃疡面愈合。再加上白芨中含有的有益成分,对于葡萄球菌、链球菌等有抑菌作用,能形成保护膜,从而起到防止胃部感染的作用。
冰片为从龙脑香的树脂和挥发油中取得的结晶,是近乎纯粹的右旋龙脑。龙脑香的树脂和挥发油中含有多种萜类成分。除龙脑外,尚含葎草烯、β-榄香烯、石竹烯等倍半萜,齐墩果酸、麦珠子酸、积雪草酸、龙脑香醇酮、龙脑香二醇酮、古柯二醇等三萜化合物。冰片苦辛性凉,长于通诸窍、散郁火、去翳明目;外用能清热消肿、止痒止痛。黄柏苦寒,功擅清热燥湿、泻火解毒;外用能燥湿敛疮。二者相伍外用,有清热泻火、解毒消肿、燥湿敛疮、止痛止痒之功效,用于治疗火热内郁上攻所引起的口腔糜烂、溃疡、口舌生疮、咽喉肿痛等症。
黄柏、紫草、莪术、五倍子、白芨和冰片共同作为臣药,主要起加强君药药效的作用,防止君药药性的流失,保障患者病灶部位能够充分吸收君药中的有效成分,从而保证了痔疮的治疗效果。
进一步地,痔疮膏的原料还可以是以下重量份计:
黄柏10份;煅石膏30份;紫草10份;当归20份;莪术10份;乳香20份;五倍子10份;煅龙骨30份;白芨10份;冰片3份;珍珠30份;炉甘石30份。
各原料采用上述配比,各原料能够充分发挥协同增效作用,可以达到更好的疗效,药材也不会存在浪费现象。
痔疮膏的原料还可以进一步包括按重量份计的以下原料:
马铃薯5-10份;甘草酸铵10-15份;山莨菪碱3-8份;蛤蚧4-9份;槐花12-16份;大黄3-7份;山茶花5-12份;青黛8-12份;皂角7-15份;无花果10-15份。
马铃薯,别称土豆、地蛋、洋芋等。中医认为马铃薯“性平味甘无毒,能健脾和胃,益气调中,缓急止痛,通利大便,对脾胃虚弱、消化不良、肠胃不和、脘腹作痛、大便不畅的患者效果显著”。可以用来主治胃痛、痄肋、痈肿、湿疹、烫伤,是和胃健中药和解毒消肿药。马铃薯中含有过氧化氢酶,过氧化氢酶是一种结合酶,是活细胞产生的具有催化功能的蛋白质。过氧化氢酶在酶中催化能力最强,它的活化能仅为8.4KJ/mol。过氧化氢酶的催化反应是利用过氧化氢使酚类、胺类、抗坏血酸等物质氧化,使对人体有害的酚类、胺类等排出体外,是线粒体外的生物氧化体系的一部分。过氧化氢酶同时具备生物转化作用,通过化学反应,使非营养物质的极性增加;也可以使某些非营养物质的生物活性降低或者消失,这也称为解毒作用,易于有害物质排出体外。
甘草中有效成分之一的甘草酸是非常珍贵的天然解毒剂,有显著的促进肾上腺皮质激素样作用,可用于人体抗衰老、抗炎症、降压、增强机体免疫力、提高生理机能、改善高血脂、维持水盐代谢平衡。甘草酸铵是甘草酸的特有结构,具有抗炎、抗过敏等方面的生理活性。目前,被广泛应用于临床。
槐花,味苦,性平,无毒,具有清热、凉血、止血、降压的功效。对吐血、尿血、痔疮出血、风热目赤、高血压病、高脂血症、颈淋巴结核、血管硬化、大便带血、糖尿病、视网膜炎、银屑病等有显著疗效;还可以驱虫、治咽炎。槐花能增强毛细血管的抵抗力,减少血管通透性,可使脆性血管恢复弹性的功能,从而降血脂和防止血管硬化。
青黛,为爵床科马蓝属植物马蓝、蓼科蓼属植物蓼蓝、豆科木蓝属植物木蓝、十字花科菘蓝属植物菘蓝的叶或茎叶经加工制得的干燥粉末或团块。性咸,寒;归肝、肺、胃经。用于清热,凉血,解毒。主治温毒斑疹,吐血,咯血,咽喉肿痛等;现代药理学证明其具有抗肿瘤、抗炎镇痛、抗溃疡、抗菌作用,对胸腺T淋巴细胞和脾脏T淋巴细胞有促进增殖的作用,可改善免疫系统功能。
皂角药用部分为豆科植物皂荚的果实或不育果实。其具有祛痰止咳;开窍通闭;杀虫散结的功效。主痰咳喘满;中风口噤;痰涎壅盛;神昏不语;癫痫;喉痹;二便不通;痈肿疥癣。
无花果具有清热生津;健脾开胃;解毒消肿的功效。主咽喉肿痛;燥咳声嘶;乳汁稀少;肠热便秘;食欲不振;消化不良,泄泻痢疾;痈肿;癣疾。用于咳喘,咽喉肿痛,便秘,痔疮。根、叶:肠炎,腹泻;外用治痈肿。
马铃薯、甘草酸铵、槐花、青黛、皂角以及无花果主要作为佐药,其能够使君药和臣药的药性逐步释放,使人体接受程度更好,治疗过程更加顺畅,同时对病灶部位起到更好的消炎、消肿、抗菌等作用。
山莨菪碱为阻断M胆碱受体的抗胆碱药,作用与阿托品相似或稍弱。其可使平滑肌明显松弛,并能解除血管痉挛(尤其是微血管),同时有镇痛作用,但扩瞳和抑制腺体(如唾液腺)分泌的作用较弱,且极少引起中枢兴奋症状。
蛤蚧入药部分一般为壁虎科动物蛤蚧除去内脏的全体。蛤蚧的功效与作用如下:益肾补肺;定喘止嗽,主肺肾两虚气喘咳嗽,虚劳咳嗽;咯血;肾虚阳痿;遗精;小便频数;消渴。
大黄主治:实热便秘、热结胸痞、湿热泻痢、黄疸、淋病、水肿腹满、小便不利、目赤、咽喉肿痛、口舌生疮、胃热呕吐、吐血、咯血、衄血、便血、尿血、蓄血、经闭、产后瘀滞腹痛、症瘕积聚、跌打损伤、热毒痈疡、丹毒、烫伤。
山茶花,为山茶科山茶属植物红山茶的花,性苦、辛,凉;归肝、肺、大肠经。用于凉血止血,散瘀消肿。主治吐血,咳血,便血,痔血,赤白痢,血淋,血崩等。现代药理学证明,其具有抗癌作用,叶和花瓣中含有的山茶皂苷能使真菌的分生孢子异常出芽。
山莨菪碱、蛤蚧、大黄以及山茶花主要作为使药,使痔疮膏中各个原料的有效成分按照其在配伍中所起的疗效直达病所,使痔疮膏见效更快,也使各原料更好地进行协同配合治疗,减少药物带来的不良反应,患者的治疗过程更加舒适。
还提供一种上述痔疮膏的制备方法,主要包括以下步骤:
当归和莪术分别采用炒当归和炒莪术,当然用户也可以自己将当归和莪术进行炒制处理,得到炒当归和炒莪术。炒当归和炒莪术有利于后期对当归和莪术的蒸馏提取,使有效成分提取的更加彻底,从而使得有效成分进行作用时更加容易被患者吸收,疗效更快、更好。本发明实施例中的当归和莪术均采用炒当归和炒莪术。
将紫草、当归、莪术、槐花、山茶花、无花果分别进行蒸馏提取,所得提取物混合得到挥发油。将蒸馏所得混合药渣(六种药渣的混合物)留存备用,挥发油备用。
马铃薯的处理包括以下步骤:
选用优质马铃薯,去除病残部分,然后去皮,清洗。将洗净的马铃薯切碎然后打成浆。所得浆液经过滤处理或者离心处理得到洁净浆液,备用。过滤或离心后所得固体残渣烘干、研磨成粉,得薯粉,备用。固体残渣中仍然保留了多种有效成分,对患者痔疮位置的生肌、愈合、保护(减少排泄过程对痔疮位置的摩擦,以及在痔疮位置表面形成保护膜,减少细菌对痔疮位置的侵扰)均起到有效作用。
将混合药渣、薯粉、黄柏、白芨、大黄和皂角共同熬制成浸膏,备用。
将煅石膏、煅龙骨、炉甘石、五倍子、乳香、冰片、珍珠均研磨成粉末状,备用。
将蛤蚧采用乙醇浸泡处理,浸泡20-30小时,乙醇浓度为98wt%。浸泡后将浸泡液以及通过挤压蛤蚧得到的液体混合进行浓缩,所得浓缩物备用。足够时间的浸泡,才能使蛤蚧内的有效成分充分溶出,提高蛤蚧的利用率,也提高最终膏剂中的有效成分占比。
将青黛进行煎煮,将煎煮所得煎煮液浓缩至80%-85wt%后,再向其中加入甘草酸铵和山莨菪碱,所得混合物研磨成粉,得添加粉,备用。
向熔化的凡士林中加入粉末状的煅石膏、煅龙骨、炉甘石、珍珠和五倍子,然后进行搅拌,搅拌至温度降低至60℃后再加入乳香、冰片、添加粉、薯粉以及挥发油,最后再加入浸膏。搅拌30-40分钟后,再加入浓缩物和洁净浆液,继续搅拌,最后加入甘油和苯甲酸,制得符合要求的膏剂。甘油用量需要根据具体情况而定,使产品能够达到膏剂要求的硬度即可;苯甲酸作为抑菌剂加入,使膏剂制备过程中的洁净程度有较好的保障。该过程中,搅拌总用时为1-3小时,搅拌转速为50-90转/分。发明人通过试验发现搅拌的时间和转速对于膏剂最后的药效有一定的影响,在上述搅拌时长以及搅拌转速内,所得膏剂的药效更好。
以下结合实施例对本发明的特征和性能作进一步的详细描述。
实施例1
本实施例提供一种痔疮膏,其主要采用以下过程进行制备:
该痔疮膏的原料包括:
黄柏6g;煅石膏25g;紫草5g;当归15g;莪术5g;乳香15g;五倍子5g;煅龙骨25g;白芨5g;冰片1g;珍珠25g;炉甘石25g。
该痔疮膏的制备方法包括:
所有原料均为粉末状,粉末粒径为100纳米。将所有粉末原料与凡士林、甘油混合,即制得痔疮膏。
实施例2
本实施例提供一种痔疮膏,其主要采用以下过程进行制备:
该痔疮膏的原料包括:
黄柏15g;煅石膏35g;紫草15g;当归25g;莪术15g;乳香25g;五倍子15g;煅龙骨35g;白芨15g;冰片5g;珍珠35g;炉甘石35g。
该痔疮膏的制备方法包括:
将紫草、当归、莪术分别进行蒸馏提取,所得提取物混合得到挥发油。将蒸馏所得混合药渣(三种药渣的混合物)留存备用,挥发油备用。
将挥发油、混合药渣以及其他原料与凡士林、甘油混合,即制得痔疮膏。
实施例3
本实施例提供一种痔疮膏,其主要采用以下过程进行制备:
该痔疮膏的原料包括:
黄柏10g;煅石膏30g;紫草10g;当归20g;莪术10g;乳香20g;五倍子10g;煅龙骨30g;白芨10g;冰片3g;珍珠30g;炉甘石30g。
该痔疮膏的制备方法包括:
将紫草、当归、莪术分别进行蒸馏提取,所得提取物混合得到挥发油。将蒸馏所得混合药渣(三种药渣的混合物)留存备用,挥发油备用。
将混合药渣与黄柏、白芨共同熬制成浸膏。再将浸膏、挥发油与凡士林、甘油混合,即制得痔疮膏。
实施例4
本实施例提供一种痔疮膏,其主要采用以下过程进行制备:
该痔疮膏的原料包括:
黄柏6g;煅石膏35g;紫草15g;当归15g;莪术5g;乳香25g;五倍子5g;煅龙骨28g;白芨15g;冰片5g;珍珠25g;炉甘石35g,马铃薯5g;甘草酸铵10g;山莨菪碱3g;蛤蚧4g;槐花12g;大黄3g;山茶花5g;青黛8g;皂角7g;无花果10g。
该痔疮膏的制备方法包括:
将紫草、当归、莪术、槐花、山茶花、无花果分别进行蒸馏提取,所得提取物混合得到挥发油。将蒸馏所得混合药渣(六种药渣的混合物)留存备用,挥发油备用。
马铃薯的处理包括以下步骤:
选用优质马铃薯,去除病残部分,然后去皮,清洗。将洗净的马铃薯切碎然后打成浆。所得浆液经过滤处理或者离心处理得到洁净浆液,备用。过滤或离心后所得固体残渣烘干、研磨成粉,得薯粉,备用。固体残渣中仍然保留了多种有效成分,对患者痔疮位置的生肌、愈合、保护(减少排泄过程对痔疮位置的摩擦,以及在痔疮位置表面形成保护膜,减少细菌对痔疮位置的侵扰)均起到有效作用。
将混合药渣、薯粉、黄柏、白芨、大黄和皂角共同熬制成浸膏,备用。
将煅石膏、煅龙骨、炉甘石、五倍子、乳香、冰片、珍珠均研磨成粉末状,备用。
将蛤蚧采用乙醇浸泡处理,浸泡20小时,乙醇浓度为98wt%。浸泡后将浸泡液以及通过挤压蛤蚧得到的液体混合进行浓缩,所得浓缩物备用。足够时间的浸泡,才能使蛤蚧内的有效成分充分溶出,提高蛤蚧的利用率,也提高最终膏剂中的有效成分占比。
将青黛进行煎煮,将煎煮所得煎煮液浓缩至80%wt%后,再向其中加入甘草酸铵和山莨菪碱,所得混合物研磨成粉,得添加粉,备用。
向熔化的凡士林中加入粉末状的煅石膏、煅龙骨、炉甘石、珍珠和五倍子,然后进行搅拌,搅拌至温度降低至60℃后再加入乳香、冰片、添加粉、薯粉以及挥发油,最后再加入浸膏。搅拌30分钟后,再加入浓缩物和洁净浆液,继续搅拌,最后加入甘油和苯甲酸,制得符合要求的膏剂。甘油用量需要根据具体情况而定,使产品能够达到膏剂要求的硬度即可。该过程中,搅拌总用时为1小时,搅拌转速为50转/分。
实施例5
本实施例提供一种痔疮膏,其主要采用以下过程进行制备:
该痔疮膏的原料包括:
黄柏8g;煅石膏27g;紫草9g;当归17g;莪术8g;乳香16g;五倍子6g;煅龙骨27g;白芨9g;冰片2g;珍珠26g;炉甘石28g,马铃薯10g;甘草酸铵15g;山莨菪碱8g;蛤蚧9g;槐花16g;大黄7g;山茶花12g;青黛12g;皂角15g;无花果15g。
该痔疮膏的制备方法与实施例4中提供的制备方法大致相同,不同之处在于:
蛤蚧在乙醇中浸泡的时间为:30小时;青黛煎煮液浓缩至85wt%后加入甘草酸铵和山莨菪碱;最后的混合搅拌过程中,加入浓缩物和洁净浆液之前已搅拌了40分钟,最后的混合搅拌过程总用时为3小时,搅拌转速为90转/分。
实施例6
本实施例提供一种痔疮膏,其主要采用以下过程进行制备:
该痔疮膏的原料包括:
黄柏11g;煅石膏32g;紫草12g;当归23g;莪术13g;乳香24g;五倍子13g;煅龙骨31g;白芨16g;冰片4g;珍珠34g;炉甘石31g,马铃薯7g;甘草酸铵13g;山莨菪碱5g;蛤蚧6g;槐花14g;大黄5g;山茶花9g;青黛10g;皂角11g;无花果12g。
该痔疮膏的制备方法与实施例4中提供的制备方法大致相同,不同之处在于:
蛤蚧在乙醇中浸泡的时间为:25小时;青黛煎煮液浓缩至82wt%后加入甘草酸铵和山莨菪碱;最后的混合搅拌过程中,加入浓缩物和洁净浆液之前已搅拌了35分钟,最后的混合搅拌过程总用时为2小时,搅拌转速为70转/分。
实施例7
本实施例提供一种痔疮膏,其主要采用以下过程进行制备:
该痔疮膏的原料包括:
黄柏9g;煅石膏34g;紫草7g;当归20g;莪术11g;乳香20g;五倍子11g;煅龙骨27g;白芨14g;冰片3g;珍珠33g;炉甘石29g,马铃薯6g;甘草酸铵11g;山莨菪碱7g;蛤蚧5g;槐花13g;大黄4g;山茶花6g;青黛9g;皂角8g;无花果11g。
该痔疮膏的制备方法与实施例4中提供的制备方法大致相同,不同之处在于:
蛤蚧在乙醇中浸泡的时间为:28小时;青黛煎煮液浓缩至84wt%后加入甘草酸铵和山莨菪碱;最后的混合搅拌过程中,加入浓缩物和洁净浆液之前已搅拌了38分钟,最后的混合搅拌过程总用时为2.5小时,搅拌转速为80转/分。
实施例8
本实施例提供一种痔疮膏,其主要采用以下过程进行制备:
该痔疮膏的原料包括:
黄柏10g;煅石膏30g;紫草10g;当归20g;莪术10g;乳香20g;五倍子10g;煅龙骨20g;白芨10g;冰片3g;珍珠30g;炉甘石30g,马铃薯9g;甘草酸铵14g;山莨菪碱7g;蛤蚧8g;槐花15g;大黄6g;山茶花11g;青黛11g;皂角14g;无花果14g。
该痔疮膏的制备方法与实施例4中提供的制备方法大致相同,不同之处在于:
蛤蚧在乙醇中浸泡的时间为:22小时;青黛煎煮液浓缩至81wt%后加入甘草酸铵和山莨菪碱;最后的混合搅拌过程中,加入浓缩物和洁净浆液之前已搅拌了32分钟,最后的混合搅拌过程总用时为1.5小时,搅拌转速为60转/分。
试验例1
急毒试验。对实施例1-8提供的痔疮膏进行试验。对小鼠给药熏蒸的半数致死量(LD50)进行了试验测定,但未测到LD50,因此进行了最大耐受量试验。结果:按成人单位体重临床日用剂量的500倍对小鼠肛门用药,十日内小鼠无一死亡,处死小鼠解剖观察各脏器未发现毒性反应,给药组与对照组小鼠无任何差异。
长毒试验。应用Wistar大鼠将实验药物设定为高、中、低三个剂量,分别按人单位体重用药量的80倍、40倍和20倍的给药量为实验组,另设一正常饲养的对照组。连续肛门给药90天、180天,部分动物停药10天后,观察对大鼠各项生理、生化指标的影响。实验结果表明:对大鼠的进食量和生长发育(体重增长)均无影响。对肝功能和肾功能均未发现明显毒性作用。对血常规、血生化、尿液生化及骨髓片等均未见明显影响,各组间与对照组比较无明显差异。
试验例2
临床试用病例如下:
罗某,男,40岁;痔疮为外痔,已患三年,每次大便有痛感,偶尔有少量便血。第一次使用本发明实施例4提供的痔疮膏后,大便无痛感,也无便血,大便变顺畅。坚持连续使用4天,每天晚上睡前擦拭一次,每天便后擦拭一次,大便无痛感,也无便血,无不适。连续使用10天后,经检查,痔疮已痊愈。
曾某,男,35岁;痔疮为中后期内痔,已患四年,大便痛感强烈,便血较多;用市售的马应龙痔疮膏治疗,并用中药清洗患部,疗效不稳,时好时坏;近期病情恶化,准备手术治疗。第一次使用本发明实施例5提供的痔疮膏后,大便痛感减轻很多,便血量减少;大便后再次擦拭痔疮膏。第二天大便时,痛感又稍有减轻,大便排出较为顺畅,便血减少更加明显。坚持连续使用5天,每天晚上睡前擦拭一次,每天便后擦拭一次。5天后大便几乎无痛感,几乎无便血。连续使用7天后,大便通畅,毫无痛感,无便血,经检查,痔疮已痊愈。
柯某,女,10岁;混合痔1年,大便有痛感,间歇性便血;使用本发明实施例6提供的痔疮膏后,当天大便顺畅,痛感不明显。连续使用5天,每天晚上睡前擦拭一次,每天便后擦拭一次。5天后大便无痛感,无便血,肛门处无不适,经检查,痔疮已痊愈。
以上所描述的实施例是本发明一部分实施例,而不是全部的实施例。本发明的实施例的详细描述并非旨在限制要求保护的本发明的范围,而是仅仅表示本发明的选定实施例。基于本发明中的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
Claims (10)
1.一种痔疮膏,其特征在于,包括按重量份数计的以下原料:
黄柏6-15份;煅石膏25-35份;紫草5-15份;当归15-25份;莪术5-15份;乳香15-25份;五倍子5-15份;煅龙骨25-35份;白芨5-15份;冰片1-5份;珍珠25-35份;炉甘石25-35份。
2.根据权利要求1所述的痔疮膏,其特征在于,所述痔疮膏包括按重量份数计的以下原料:
所述黄柏10份;所述煅石膏30份;所述紫草10份;所述当归20份;所述莪术10份;所述乳香20份;所述五倍子10份;所述煅龙骨30份;所述白芨10份;所述冰片3份;所述珍珠30份;所述炉甘石30份。
3.根据权利要求1或2所述的痔疮膏,其特征在于,所述痔疮膏还包括按重量份数计的以下原料:
马铃薯5-10份;甘草酸铵10-15份;山莨菪碱3-8份;蛤蚧4-9份;槐花12-16份;大黄3-7份;山茶花5-12份;青黛8-12份;皂角7-15份;无花果10-15份。
4.一种如权利要求1-3任一项所述的痔疮膏的制备方法,其特征在于,包括:
将所述黄柏、所述煅石膏、所述紫草、所述当归、所述莪术、所述乳香、所述五倍子、所述煅龙骨、所述白芨、所述冰片、所述珍珠和所述炉甘石与凡士林、甘油混合制得所述痔疮膏。
5.根据权利要求4所述的痔疮膏的制备方法,其特征在于,混合各原料之前,将所述紫草、所述当归和所述莪术分别进行蒸馏提取,所得提取物混合得到挥发油,再将所述挥发油与其他原料进行混合。
6.根据权利要求5所述的痔疮膏的制备方法,其特征在于,再将所述挥发油与其他原料进行混合之前,将所述紫草、所述当归和所述莪术蒸馏提取所剩余的药渣与所述黄柏、所述白芨共同熬制成浸膏,再将所述浸膏与所述挥发油和其他原料混合。
7.根据权利要求6所述的痔疮膏的制备方法,其特征在于,将所述浸膏与所述挥发油和其他原料混合之前,向熔化的凡士林中加入所述煅石膏、所述煅龙骨、所述炉甘石、所述珍珠和所述五倍子,搅拌至温度降低至60℃后再加入所述乳香、所述冰片以及所述挥发油,最后再加入所述浸膏。
8.根据权利要求7所述的痔疮膏的制备方法,其特征在于,所述煅石膏、所述煅龙骨、所述炉甘石、所述五倍子、所述乳香、所述冰片、所述珍珠均为粉末状。
9.根据权利要求7所述的痔疮膏的制备方法,其特征在于,加入所述浸膏后,继续搅拌,再向搅拌后所得混合物内加入甘油和苯甲酸。
10.根据权利要求9所述的痔疮膏的制备方法,其特征在于,搅拌时间为1-3小时,搅拌转速为50-90转/分。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910365687.1A CN109908312B (zh) | 2019-04-30 | 2019-04-30 | 一种痔疮膏及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910365687.1A CN109908312B (zh) | 2019-04-30 | 2019-04-30 | 一种痔疮膏及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109908312A true CN109908312A (zh) | 2019-06-21 |
CN109908312B CN109908312B (zh) | 2021-10-08 |
Family
ID=66978928
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910365687.1A Expired - Fee Related CN109908312B (zh) | 2019-04-30 | 2019-04-30 | 一种痔疮膏及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109908312B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1279987A (zh) * | 2000-06-26 | 2001-01-17 | 凌朝坤 | 一种治疗痔疮的药 |
US20060045924A1 (en) * | 2004-08-31 | 2006-03-02 | Lily Chen | Dried fruit composition with laxative effects and method for administration thereof |
CN109985101A (zh) * | 2017-12-30 | 2019-07-09 | 西安郑继堂药业有限公司 | 一种治疗痔疮的药膏及散剂药物及其制备方法 |
CN110420303A (zh) * | 2019-07-11 | 2019-11-08 | 潘俞成 | 一种行气活血的中药配方及其应用 |
-
2019
- 2019-04-30 CN CN201910365687.1A patent/CN109908312B/zh not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1279987A (zh) * | 2000-06-26 | 2001-01-17 | 凌朝坤 | 一种治疗痔疮的药 |
US20060045924A1 (en) * | 2004-08-31 | 2006-03-02 | Lily Chen | Dried fruit composition with laxative effects and method for administration thereof |
CN109985101A (zh) * | 2017-12-30 | 2019-07-09 | 西安郑继堂药业有限公司 | 一种治疗痔疮的药膏及散剂药物及其制备方法 |
CN110420303A (zh) * | 2019-07-11 | 2019-11-08 | 潘俞成 | 一种行气活血的中药配方及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN109908312B (zh) | 2021-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Panda | Handbook on medicinal herbs with uses: medicinal plant farming, most profitable medicinal plants in India, medicinal plants farming in India, plants used in herbalism, medicinal herbs you can grow, medicinal herbs and their uses, medicinal herbs, herbal & medicinal plants, growing medicinal herb, most profitable medicinal herbs growing with small investment, herbal medicine herbs | |
CN104208245B (zh) | 手足癣中药药浴及制备方法 | |
CN105166544A (zh) | 一种猪配合饲料及其制备方法 | |
CN104206916A (zh) | 一种用于治疗鲫鱼鱼怪病的功能性饲料及其制备方法 | |
CN103877247A (zh) | 用于治疗褥疮的药物及其制备方法 | |
CN101244109A (zh) | 天然中药烧伤烫伤治疗油水搽剂及其制备方法 | |
CN106389881A (zh) | 一种活血散瘀膏 | |
CN110652552A (zh) | 一种伤口愈合配方及制备方法 | |
CN109908312A (zh) | 一种痔疮膏及其制备方法 | |
CN103860977B (zh) | 一种治疗皮炎的药物组合物 | |
JAAFAR et al. | The Use of Pharmaceutical Preparation of Phytosome Lepidium Sativum Extract as Anti-diarrheal Induced by the Bacteria E. coli in Mice. | |
CN104623040A (zh) | 一种用于创口杀菌消炎的护理组合物及其制备方法 | |
CN104306465B (zh) | 一种治疗结石的中药组合物及其片剂制备方法 | |
CN115414427B (zh) | 治疗慢性皮肤瘙痒症的中药组合物及其制备方法、用途 | |
CN108186901A (zh) | 一种用于烧烫伤的米蒿复方制剂及其制备方法 | |
KR20090126469A (ko) | 혈당 강하용 생약 조성물 | |
CN106138740A (zh) | 一种用于治疗气虚血瘀型缺血性中风的中药汤剂 | |
KR20090016115A (ko) | 한방 미백 조성물 및 그 제조방법 | |
CN104189195B (zh) | 治疗神经性皮肤瘙痒的中药药浴及制备方法 | |
CN107441387A (zh) | 一种用于治疗湿热体质痤疮的中药方剂 | |
CN105168779A (zh) | 一种治疗皮肤过敏的药剂 | |
CN109771502A (zh) | 一种治疗小儿红屁股与褥疮的液体敷料、其制备方法及应用 | |
CN104784666A (zh) | 一种骨科护理用中药药膏 | |
CN105125926A (zh) | 用于治疗烧烫伤的药粉及制备方法 | |
CN105056073A (zh) | 医治心律失常的中药制剂及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20211008 |